Prescribing and medical non-adherence after myocardial infarction: qualitative interviews with general practitioners in Germany by Freier, Christian et al.
RESEARCH ARTICLE Open Access
Prescribing and medical non-adherence
after myocardial infarction: qualitative
interviews with general practitioners in
Germany
Christian Freier1*, Christoph Heintze1 and Wolfram J. Herrmann1,2
Abstract
Background: An increasing prevalence of having survived a myocardial infarction increases the importance of
medical secondary prevention. Although preventive medication reduces mortality, prescribing and adherence are
known to be frequently insufficient. General practitioners are the most important prescriber. However, their
perspective on prescribing and medical non-adherence following myocardial infarction has not yet been explored.
Thus, the aim of this study was to explore the general practitioners’ perspective on long-term care after myocardial
infarction focussing on medical prevention.
Methods: In this qualitative interview study we conducted episodic interviews with sixteen general practitioners
from rural and urban surgeries in Germany. Framework analysis with focus on general practitioners’ prescribing and
patients’ non-adherence was performed.
Results: Almost all general practitioners reported following guidelines for myocardial infarction aftercare and
prescribing the medication that was initiated in the hospital; however, they described deviating from guidelines
because of drugs’ side effects or patients’ intolerances. Some questioned the benefits of medical secondary
prevention for the oldest of patients.
General practitioners perceived good adherence among their patients who had had an MI while they regarded
their methods for assessing medical non-adherence as limited. They perceived diverse reasons for non-adherence,
particularly side effects, patients’ freedom from symptoms and patients’ indifference to health. They attributed
mainly negative characteristics, like lack of knowledge and understanding, to non-adherent patients. These
characteristics contribute to the difficulty of convincing these patients to take medications as prescribed.
General practitioners improved adherence by preventing side effects, explaining the medication’s necessity,
facilitating intake and involving patients in decision-making. However, about half of the general practitioners
reported threatening their patients with negative consequences of non-adherence.
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Conclusions: General practitioners should be aware that discharge medication can be insufficient and thus, should
always check hospital recommendations for accordance with guideline recommendations. Improving physicians’
communication skills and informing and motivating patients in an adequate manner, for example in simple
language, should be an important goal in the hospital and the general practitioner setting. General practitioners
should assess patients’ motivations through motivational interviewing, which no general practitioner mentioned
during the interviews, and talk with them about adherence and long-term treatment goals regularly.
Keywords: Family practice, General practice, Primary care, Myocardial infarction, Secondary prevention, Prescribing,
Medication adherence, Qualitative research, Interviews
Background
Globally, coronary heart disease (CHD) accounted for
8.93 million deaths in 2017 [1]. The incidence of myo-
cardial infarction (MI) is declining in Germany and the
USA [2, 3]; however, the case fatality rate is also decreas-
ing, with an increasing percentage of patients surviving
MI in Europe and the USA [3, 4].
Secondary preventive medication significantly reduces
MI survivors’ mortality [5, 6]. According to current
guidelines for both ST-elevation myocardial infarction
(STEMI) [7, 8] and non-ST-elevation myocardial infarc-
tion (NSTEMI) [9, 10], aspirin and statins are recom-
mended and beta-blockers and angiotensin converting
enzyme inhibitors (ACEI) should be considered, each
unless there are contraindications. Angiotensin receptor
blockers (ARB) are an alternative to ACEI [7–10]. P2Y12
inhibitors for dual antiplatelet therapy (DAPT) are usu-
ally recommended for twelve months [7–10].
General practitioners (GPs) play an important role in
long-term care after MI [11–14]. In Germany 97% of pa-
tients visited a GP in the fourth quarter after their MI
while only 23% visited an office-based cardiologist [14].
However, only 44% of these patients had prescriptions
for all four drug groups (aspirin and P2Y12 inhibitors as
one group, ACEI and ARB as one group) filled in the
quarter of their MI, decreasing to 24% in the fourth
quarter after MI [14]. Furthermore, it has been shown
that outpatient prescribing of the recommended drugs
following MI is suboptimal [15–19]. Questionnaire stud-
ies with GPs explored reasons for not prescribing these
drugs, including side effects, intolerances and contraindi-
cations [20–22]. However, these studies were not open
for emerging reasons which were not addressed by the
questionnaires [20–22]. In one of these studies about
prescribing of beta-blockers the preparation of the ques-
tionnaire included, among other sources, interviews with
physicians, but it has not been shown which items they
contributed to the final questionnaire [20]. Additionally,
some qualitative studies with GPs focused on the pre-
scribing of statins [23–25], but none of them focused on
secondary prevention and there is a lack of qualitative
studies addressing the prescribing of the other recom-
mended drugs.
Known factors associated with low prescribing rates are
the type of MI [19, 26] as well as the gender [15, 27] and
age of patients [15, 16, 22, 27, 28]. Prescribing seems to be
lower in patients after NSTEMI [19, 26], but reasons for
this are unknown. Prescribing is also lower in women after
MI or coronary revascularisation than in men [15, 27].
Women reported more frequent side effects under statins
[29], and their antiplatelet therapy has been more fre-
quently stopped in case of bleeding after MI [30]. A strong
factor in gender disparities around statin prescription in
CHD was women’s higher age [14, 29]. The prescribing of
secondary preventive medication is also lower in older pa-
tients [15, 16, 22, 27, 28]. Qualitative research investigat-
ing reasons for this gap in secondary prevention is limited
to a study with GPs from the Netherlands, which revealed
uncertainties relating to guidelines, doctors, patients and
organisation [31]. Comorbidities may lead to deviation
from guidelines since guidelines rarely address such com-
plexities [32].
Non-adherence to medication following MI is also a
known issue [33]. Knowledge of possible reasons for
non-adherence enables physicians to recognise individ-
ual barriers to adherence [34, 35]. However, few studies
have reported the ways in which physicians assess adher-
ence to secondary preventive medication [36]. In
addition, to our knowledge, physicians’ perceptions of
reasons for non-adherence after acute coronary syn-
drome have only been studied for Clopidogrel in the
USA and the perceived main reason were the costs for
the patients [37]. However, this seems to be specific for
the USA, e.g. in Germany most of the costs are covered
by statutory health insurances.
As shown, GP care is crucial for medical prevention
after MI; however, the GPs perspective on long-term
care after MI has been unknown yet.
Thus, the aim of this study was to research the GPs’
perspective on long-term health care following MI. For
this article we focus on the GPs’ perspective on prescrib-
ing and medical non-adherence as well as their attempts
to improve adherence.
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Methods
This qualitative interview study is part of a larger project
examining long-term care after MI in the GP setting. Be-
tween March and June 2018 we conducted face-to-face,
semi-structured, episodic interviews with GPs working
in the German federal states of Berlin (urban) and Bran-
denburg (rural).
Several recruitment strategies were applied to achieve
a sample with a broad diversity [38] regarding GPs’ age
and the number of physicians in each surgery and with a
nearly equal distribution of GPs’ genders and of the
number of surgeries located in each of the two federal
states: advertising in a newsletter of the Research Net-
work of the Berlin Institute of General Practice Charité
(ANCHOR), personal letters to GPs who had recruited
patients for another interview study of this project about
patients’ perspectives on long-term care after MI, and
asking GPs who were working in teaching surgeries of
the Charité – Universitätsmedizin Berlin during a work-
shop. Sixteen GPs were recruited and interviewed: three
GPs who responded to the newsletter, six of the ten GPs
who got a personal letter and seven of the twenty-two
workshop participants. Table 1 gives an overview of par-
ticipants’ characteristics.
Based on the assumption that ‘subjects’ experiences of
a certain domain are stored and remembered in form of
narrative-episodic and semantic knowledge’, episodic in-
terviews are a method to access both of these forms, en-
abling in-method triangulation between these [38].
‘Episodic knowledge is [...] linked to concrete situations
and circumstances’ and made accessible by prompts for
case narratives [38]. Accordingly, GPs were repeatedly
encouraged to narrate cases of their patients who had
had an MI some time ago. Furthermore, these case
narratives can balance social desirability effects. Seman-
tic knowledge, which contains ‘concepts and their rela-
tion to each other’, ‘is made accessible by concrete
pointed questions’ [38].
An interview guide (Additional file 1) covering differ-
ent aspects of GPs’ long-term care for these patients was
developed. It was then revised in collaboration with
other qualitative researchers from our institute during a
workshop after they had been informed about the aim of
the study. The guide was tested in two pilot interviews
and served for the interviewers’ orientation during the
interviews.
The first author conducted the interviews. He was
knowledgeable about long-term care after MI and re-
ceived training in conducting qualitative interviews. He
was in no relationship to the participants. To facilitate
GPs’ participation and to make them comfortable in the
interviews the GPs determined the interview settings: fif-
teen were conducted in GPs’ surgeries and one at a GP’s
home. The interviews had a mean duration of 71 min
(SD = 18 min) and were audio recorded. Context records
and, if necessary, post-interview-memos were made [38].
The first author transcribed the recordings verbatim
after each interview and anonymised them. A summary
was written for each interview. After each transcription,
the interview was searched for emergent themes and as-
pects of themes which matched the researched question
and were not addressed by the interview guide [39]. En-
tirely new themes were added to the guide as new ques-
tions after emerging in three of the conducted interviews.
New aspects belonging to themes which were already con-
tained in the guide were added to the guide as new ques-
tions after emerging in one of the conducted interviews.
The new questions were then applied to all remaining in-
terviews. In the interview guide (Additional file 1) these
new questions are written in italics and commented with
the number of the interview to which they were applied
for the first time. In the five last interviews no new themes
or aspects emerged. Therefore, saturation was assumed.
To analyse the qualitative data, we applied Ritchie and
Spencer’s framework analysis [40]. It addresses both a
priori issues and freshly emergent themes, improves
transparency [41] and allows a comprehensive review of
the data [40]. By conducting the interviews, transcribing
and re-reading summaries, the first author became fa-
miliar with the data and set up a thematic framework.
The first and the last author consecutively elaborated
the framework with each of the following steps: incorp-
orating the interview guide; testing the framework on
three of the later interviews, which varied according to
GP and surgery characteristics; coding all transcripts
with the software f4analyse 2.0.3 EDUCATION; review-
ing the coding in a workshop with experienced qualita-
tive researchers; final elaboration of the categories which
Table 1 Characteristics of interviewed GPs. Percentages of the





Number of interviewed GPs 9 (57) 7 (44)
Gender
Female 5 (31) 4 (25)
Male 4 (25) 3 (19)
Age (range: 38–64 years)
35–44 2 (13) 3 (19)
45–54 3 (19) 2 (13)
55–64 4 (25) 2 (13)
Number of physicians in surgery
1 3 (19) 1 (6)
2 2 (13) 5 (31)
3 2 (13) 0 (0)
4 or more 2 (13) 1 (6)
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concerned medication; and final coding of these categor-
ies. For each category concerning medication, summar-
ies of the corresponding coded text segments for every
GP were tabulated.
All participants gave written informed consent. The
local ethical committee approved the study.
The first author translated the quotes into English. All
quotes are marked with the gender (F = female, M =
male) and the surgery location (B = Berlin, BB = Bran-
denburg) of the respective interviewee.
Results
Analysis of the data regarding medical therapy after MI
revealed two major topics: ‘Prescribing of medication
after MI’ focuses on GPs’ prescribing behaviour; ‘Non-
adherence of patients’ focuses on GPs’ perspectives on
patients’ non-adherence. Table 2 shows the topics’ sub-
themes. In the following, we will elaborate on these
topics. The subthemes’ subcodes are also listed in
Additional file 2.
Prescribing of medication after MI
Prescribed medications
The interviewed GPs claimed to prescribe ACEI, beta-
blockers, aspirin and statins for all or most patients who
had had an MI, as recommended by guidelines:
‘[...] that are always ACE inhibitor or a sartan, beta-
blocker, a statin and ASS 100 [aspirin].’ (GP2, M, BB)
An exception from this was one GP who stated that he
did not see any necessity for statins in patients after MI
with normal lipid values.
However, when the GPs were asked about a recent
consultation with a patient who had had an MI, it was
revealed that almost half of the interviewed GPs had not
prescribed one or two of the recommended drugs in the
respective case.
Hospital recommendations
Almost all interviewed GPs reported that they continued
prescribing the medication initiated in the hospital, with
a few expressing their trust in the inpatient cardiologists:
‘What I prescribe is recommended to me by the
hospital, and then I don’t enquire properly. They are
absolute experts in the hospital.’ (GP5, F, B)
Only one GP made the point that he would not adopt
hospitals’ recommendations if they were nonsense, al-
though that had never been the case, while another GP
emphasised that she calls the hospital if there is an in-
consistency in the discharge letters.
However, one GP complained that some patients are
discharged on medication which has already been
proven to be inappropriate for them. She therefore in-
cludes information about every patient’s prior medica-
tion on the admission form.
Cardiologists’ role in GPs’ prescribing
In Germany office-based cardiologists usually run their
own surgeries, and GPs can refer patients to these cardi-
ologists. All interviewed GPs stated that they prescribe
medication for secondary prevention themselves. How-
ever, some GPs explained that it is hard to keep track of
the recommendations for DAPT and triple therapy and
another GP said that she is inexperienced in prescribing
sacubitril/valsartan combination or ranolazine. Thus,
they leave decisions regarding such questions to office-
based cardiologists. The majority of interviewed GPs said
that they get recommendations and feedback regarding
medication from office-based cardiologists.
GPs’ perspectives on the impact of NSTEMI, patients’ gender
and patients' age on prescribing
None of the GPs reported that they distinguished be-
tween NSTEMI and STEMI regarding prescribing:
‘That’s why in my view there are no big differences
in the administration [of drugs], because both
involve a corresponding obstruction of vessels and a
destruction of tissue [...].’ (GP4, M, B)
Most GPs claimed that neither patients’ gender nor pa-
tients’ age matters to them for prescribing after MI:
‘Primarily it doesn’t matter. So from the approach,
[the patient] has a cardiac infarction, gets [medication]
now, it remains like that.’ (GP1, F, BB)
Table 2 Major topics and subthemes
Major topic 1: Prescribing of medication after MI
- Prescribed medications
- Hospital recommendations
- Cardiologists’ role in GPs’ prescribing
- GPs’ perspectives on the impact of NSTEMI, patients’ gender and
patients' age on prescribing
- Further reasons for not prescribing guideline recommended
medication
Major topic 2: Non-adherence of patients
- GPs’ perception of non-adherence
- Assessing medical non-adherence
- Attributed reasons for non-adherence
- Improving adherence
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The only factor stated which was concerned with pa-
tients’ gender was erectile dysfunction as a potential side
effect of beta-blockers. A few GPs stated polypharmacy
as a reason for prescribing fewer drugs for the elderly
after MI. Some GPs argued that older patients might not
live long enough to benefit from secondary prevention,
while others perceived a higher risk for side effects in
older patients:
‘Very old people, [...] that is the group of those in
whom you often have to deal with polypharmacy
and prioritisation. [...] Especially in statins the thing
is that it is a question of preventive effects, and I
personally doubt the preventive effect of a
consequent cholesterol reduction in someone who is
over 90 [years old].’ (GP14, M, B)
Further reasons for not prescribing guideline recommended
medication
Initially, half the GPs emphasised that there are no
reasons for not prescribing guideline recommended
medication after MI. However, all GPs then went on
to state at least one reason, most stated several rea-
sons. The most important of these were side effects
or intolerances, both of which were named by all
GPs:
‘Well, sometimes under statins one has myopathies,
elevations of CK [creatine kinase] or myoglobin or
gamma-GT, in case of intolerance, then I
discontinue it [...].’ (GP13, F, B)
The majority of the GPs also stated contraindicating
comorbidities as reasons for not prescribing, most fre-
quently gastric ulcer contraindicating aspirin. A few
GPs claimed guidelines are not adequate to every pa-
tient as there are no recommendations for complicat-
ing factors such as side effects, comorbidities and
polypharmacy.
Further stated reasons for not prescribing the recom-
mended drugs were patients refusing medication, a need
for other, more important drugs which can not be given
with recommended medication after MI, anticoagulation
instead of antiplatelet therapy, palliative situations and
patients not tolerating normotonia.
Non-adherence of patients
GPs’ perception of non-adherence
The majority of the GPs reported that only a few of their
patients are non-adherent to medication after MI:
‘Well, I would generally say that the adherence [after
MI] is pretty good. Well, here in our area [stated the
district] and among our patients.’ (GP6, F, B)
However, some GPs emphasised that non-adherence is
the main challenge in the long-term care after MI. Ac-
cordingly, some GPs reported finding it laborious to
keep trying to convince their patients to take their
medication.
Assessing medical non-adherence
GPs reported that their methods for assessing medical
non-adherence were limited. All GPs check the days
covered by the last prescriptions or the intervals between
prescriptions:
‘When I really see that prescriptions really have long
intervals, so when there are long intervals, then I ask
[the patient] [...].’ (GP14, M, B)
A few GPs explained that they prescribe aspirin, al-
though it is an over-the-counter drug, in order to moni-
tor adherence. Some GPs explained that this checking
for prescriptions has its limitations as some patients do
not fill their prescriptions or fill them but do not take
the medication. Thus, some GPs stated that they ask
their patients explicitly in every consultation whether
they still take all the drugs in the medication plan. How-
ever, this approach only works if patients are honest:
‘[…] then you ask the patients, “Are you still taking
it [the medication] like that?” […]. And I think that
then you will figure it out if they are honest.’ (GP12,
F, BB)
Some of the interviewed GPs considered unimproved
blood pressure or lipid values as indicators of medical
non-adherence.
Attributed reasons for non-adherence
GPs stated many reasons for non-adherence, which can
be sorted into two classes: one concerning patients’
characteristics and the second concerning any other
reasons.
One of the most frequently described patient charac-
teristics as a reason for non-adherence was ‘indifference
to health’:
‘Well, you will always have a certain clientele […]
who will never follow recommendations, and every-
one finds a reason. One [patient] has just watched a
telecast, another one says, “I don’t care”.’ (GP3, M, B)
Another GP highlighted indifference to health with ig-
noring of, carelessness with and disinterest in health:
‘Well, it is often the case that they [the patients] are
incredibly ignoring to their own lives. [...] but, to be
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honest, it confirms my daily experience that the
people are not very careful about their lives. [...]
Honestly, I thought that they are so interested in
their own health that they come [to me] by
themselves. But of course that is not the case.’ (GP2,
M, BB)
To highlight indifference to health one GP told of a
medical student who did an internship in her surgery:
‘Well, one [medical student] was somehow really
shocked which attitude many people have to their
lives. I think that one can’t always imagine this, [...]
that there are people who actually have no interest
[in their health]. But that is the reality.’ (GP16, F, B)
Additionally, some GPs stated that several patients do
not have the capacity to understand why they have to
take these drugs:
‘We have already addressed the topic – let me put it
this way now – intellect [of the patient]. That was
the only reason [for the patient’s non-adherence].
Indifferent because [he] not at all understood what
it is about.’ (GP3, M, B)
Some GPs also stated repression of symptoms and dis-
eases due to fear of further health issues and acute
events, and some stated downplaying of diseases:
‘Well, the discussion about his blood pressure was
always like this: [patient:] “I already had a high
blood pressure 20 years ago at your father’s
[surgery]” – [GP:] “Okay, yes. But that doesn’t mean
that it is good that you have a high blood pressure”
– “I have always had a high blood pressure”. Like
this. It is very difficult to argue with him again and
again what the blood pressure does and that it
doesn’t matter whether it was already high 20 years
ago and blah blah blah. He sees this differently. I
would say that he has another world view.’ (GP8, F, B)
A few GPs stated repression of symptoms and diseases
and lack of understanding as well as freedom from
symptoms also as reasons for patients’ unwillingness to
make lifestyle changes including continued smoking.
One GP emphasised that non-adherent patients often
have had an unhealthy lifestyle, including smoking and
alcohol abuse, for their whole lifetime.
Other reasons in the category of patients’ characteris-
tics included aversion to medications, having other pri-
orities, poverty, depression and physical disability.
Almost half of the GPs deemed men less adherent to
medication following MI than women and reasoned this
with less health consciousness and consequently less at-
tention to and efforts regarding health in men. Accord-
ingly, a few of these GPs reasoned men’s non-adherence
with freedom from symptoms and repression of diseases.
One GP emphasised that men would deem their MI a
weakness. A few GPs also reasoned men’s non-adherence
with less diligence and orderliness compared to women.
In addition to patient characteristics, GPs reported
further reasons for medical non-adherence. Those rea-
sons are mainly related to side effects and a decreasing
subjective need to take the medication over time:
The most important reason is perceived side effects,
which lead to autonomous discontinuations by the pa-
tients. A few GPs complained that they come to know
about these discontinuations some time after they have
happened. One GP emphasised that this is often the
physicians’ fault:
‘So the physicians don’t tell the patients, “Well, you
get a medication now, it is new to you, it’s called
ACE [inhibitor]. Most frequent side effect is dry
cough. Don’t discontinue, visit me!”.’ (GP3, M, B)
Some GPs said that adherence following MI depends
on the severity of patients’ symptoms and those patients’
acuity as well as the consequently perceived threat to life
during MI and on the perception of the acute care, all of
which create a frightening situation, which patients do
not want to experience again. However, two GPs empha-
sised that patients’ memories of the MI fade away. One
of them said that he reminds his patients of the negative
feelings they had experienced during their MI. Another
GP emphasised the importance of informing patients
about the necessity of the recommended medication
right after their MI. However, some GPs claimed that
patients get insufficient information about the medica-
tion’s effects and necessity in the hospital. Later, due to
freedom from symptoms, patients often see no need for
continuing with their medication. This reason for non-
adherence was stated by half of the GPs:
‘They would probably say [that] they don’t notice
anything [of the medication]. It is not that the
[survived] cardiac infarction hurts right now, and
when they take the medication they don’t feel better
but also not worse.’ (GP5, F, B)
Improving adherence
Most GPs regard it as one of their roles to improve the
adherence of their patients. GPs use different strategies
to improve medical adherence, which can be clustered
into four main strategies: preventing side effects,
explaining the medication’s necessity, facilitating the in-
take and involving patients in decision-making.
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Almost all GPs stated that they try to prevent side ef-
fects before discontinuing the drug causing them, for ex-
ample by reducing the dose:
‘Some get problems with their stomach, [...] then you
can try reducing to 75 milligrams [of aspirin] for
example.’ (GP10, M, BB)
Other strategies include changing substance or drug
class, changing distribution of daily doses and prescrib-
ing co-medication like proton pump inhibitors.
Another important measure is to explain the medica-
tion’s necessity. About half of the GPs do this highlight-
ing the negative consequences of non-adherence,
including the chance of dying:
‘[...] then I say [to the patients], “This is vital for life,
aspirin”. […] and then I say, “This is vital because
the stent shuts or can shut, and then you are dead,
immediately”.’ (GP11, F, BB)
Another GP explained as well that her way of dealing
with non-adherence is to threaten with negative
consequences:
‘Then I give him [the patient] a proper talking-to
and tell him that he had luck with the cardiac
infarction this time, that it was a close shave. It also
could have been that he would have got it [the MI]
somewhere way out in the sticks. He likes hiking;
then he could have got it somewhere on the
mountain, there nobody can help him then, and then
he bites the dust there. So I rather call a spade a
spade [...].’ (GP5, F, B)
The GPs also stated explaining the drug’s effects,
drawing analogies, such as calcified pipes, referring to
studies, showing risk scores and using visualisation.
The majority of the GPs also stated that they take differ-
ent strategies to facilitate the intake, such as polypills.
However, the majority of GPs was sceptical towards the
management of a polypill therapy after MI. A polypill is
especially seen as difficult to adhere to since a separation
of its components is not possible but sometimes needed
due to intolerances or a change of the components’ doses:
‘Well, that, when side effects occur then, then you
can’t discontinue something so easily or reduce or
so.’ (GP7, F, BB)
Other stated strategies to facilitate the intake were pre-
scribing nurse-prepared medication, prescribing once-
daily doses, discontinuation of less important drugs and
recommending pill organisers.
Half of the GPs claimed that they involve patients in
decision-making:
‘So as a GP you have to manage this balancing act
[between guidelines and what patients want], that
you have to [...], I would say, also make target
agreements with the affected person.’ (GP3, M, B)
They highlighted that it is a process of negotiating as
the following quote shows:
‘He [the patient] noted sometime that these panic
attacks and this discomfort [...], that this doesn’t
appear that often when he omits the beta-blocker.
He discontinued it, and then I said, “Well, but take
a half dose at least, see how it goes then”. And we
sort of negotiated about it.’ (GP9, M, BB)
The majority of the interviewed GPs emphasised that
ultimately, the patients have to make decisions and are
responsible for their health. Accordingly, the majority
explained that they accept medical non-adherence after
they have tried to convince their patients:
‘Then I often say, “However, to my father I would
administer it now, would insist that he takes it”.
And if they [the patients] don’t take it then, it will
be their decision.’ (GP12, F, BB)
Discussion
In this article, we examined the GPs’ perspective on
long-term care after MI regarding prescribing and med-
ical non-adherence following MI. Almost all GPs re-
ported that they follow guidelines independently of
patients’ type of MI and gender and that they continue
to prescribe the medication that was initiated in the hos-
pital. Some GPs reported uncertainties regarding DAPT
and triple therapy and that office-based cardiologists
support them in such cases. Main reasons for not pre-
scribing guideline-recommended medication were side
effects and intolerances and comorbidities. A few GPs
claimed lacking recommendations for these factors and
for polypharmacy. Some GPs question the effects of sec-
ondary prevention for the oldest of patients.
The interviewed GPs perceived good adherence to sec-
ondary preventive medication among their patients who
had had an MI while they regarded their methods for
assessing medical non-adherence as limited.
The GPs perceived diverse reasons for non-adherence,
particularly side effects, patients’ freedom from symp-
toms and indifference to health. Another important rea-
son was patients’ lack of knowledge and understanding.
Some GPs claimed that patients get insufficient informa-
tion about the medication in the hospital.
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The GPs’ strategies for improving adherence include
preventing side effects, explaining the necessity of the
medication, facilitating intake and involving patients in
decision-making. About half of them reported threaten-
ing their patients with negative consequences of non-
adherence.
Comparison with existing literature
Our findings relating to GPs’ perspective on reasons for not
prescribing recommended medication following MI are in
accordance with quantitative findings after MI [20–22] and
qualitative findings in statin therapy [23–25]. The fact that
guidelines rarely address complicating factors such as co-
morbidities [32] was claimed by GPs in our study too.
However, contrary to a few GPs’ opinion, recent guidelines
for STEMI and for NSTEMI by the European Society of
Cardiology [7, 9] and by the American Heart Association
and the American College of Cardiology [8, 10] do address
side effects or intolerances and contraindicating comorbidi-
ties. However, they do not address multimorbidity and con-
sequential polypharmacy [7–10].
In contrast to studies showing lower prescribing after
NSTEMI [19, 26] and in women [15, 27], GPs negated
prescribing differently in these sub-groups. It is already
known that discharge medication prescribed by the hos-
pital after an MI is insufficient [19, 42]; however, inter-
viewed GPs stated that they usually adhere to these
recommendations. A possible reason for this non-
guideline recommendation in discharge letters might be
the older age of NSTEMI patients [19, 42] and female
MI patients [12, 43].
Our findings regarding GPs’ perspective on reasons for
not prescribing recommended medication in older pa-
tients correspond with qualitative findings for statins
[23, 36] and post-MI prescribing in the elderly [31].
However, in contrast to a focus group study from the
Netherlands, our study has not revealed barriers relating
to organisation, such as the finding that many patients
had fallen into the gap between secondary and primary
care and were no longer visiting their specialist [31].
GPs perceived good adherence to secondary preventive
medication following MI. This is in contrast to a study
which has shown that adherence after MI is insufficient
[33] and underlines that their adherence assessment is
limited. That physicians assess non-adherence by check-
ing prescription refill records [36], by asking the patients
[44, 45] and by monitoring lipid values [36] has also
been reported in previous studies. Furthermore, GPs’
view that adherence depends on patients’ experiences
during MI is in accordance with findings from interviews
with patients after MI [46].
GPs perceived side effects and patients’ freedom from
symptoms as reasons for non-adherence. These percep-
tions have also been reported by GPs in studies which
have addressed statin therapy [23, 25]. Some GPs also per-
ceived indifference to health as a reason for non-
adherence, and they mainly described it as a character
trait. In line with this, a previous study found that patients
with greater concern about heart health were more open
to statins’ benefits [25]. However, to our knowledge, indif-
ference to health as a reason for non-adherence has not
been reported before in the literature, although most of
the reasons for non-adherence perceived by the GPs in
this study are in accordance with those reported by pa-
tients in previous studies [25, 34, 37, 47–49]. This implies
that indifference to health might be only the GPs’ percep-
tion. What GPs perceive as indifference to health might in
fact be a functional behaviour of the patient to try to re-
duce ambivalence and fear, such as coping-behaviour. An-
other explanation might be that some patients have other
values and priorities than the GPs, which might be per-
ceived as indifference to health. Further explanations
might be an external health locus of control [50], low self-
efficacy [51] and patients’ freedom from symptoms.
The reported characteristics of non-adherent patients,
such as patients’ lack of knowledge and understanding,
were mainly negative and promote the laboriousness of
convincing these patients. This indicates a helplessness
of the GPs in the management of these patients.
One potential method for exploring underlying mo-
tives and motivations is motivational interviewing [52].
Motivational interviewing can improve adherence, but
studies demonstrating this in the context of medical ad-
herence in cardiovascular diseases are scarce [52, 53].
Accordingly, none of the GPs mentioned the use of mo-
tivational interviewing, although we explicitly asked
them about their strategies for improving adherence.
This is in accordance with the finding that GPs who
were working in Berlin, Germany, showed a low to mod-
erate use of motivational interviewing techniques during
individual risk counselling with overweight or obese pa-
tients during which any medical problem requiring a de-
cision occurred [54]. The interviewed GPs might use
techniques of motivational interviewing without naming
it. However, they reported to confront their patients
with the danger of death and expected ratio-based inter-
ventions such as education to be successful, which con-
tradicts the approach of motivational interviewing.
Physicians’ reported strategies for improving adher-
ence through preventing side effects [25, 36], education
[24, 25, 36, 45, 55], reduced frequency of administration
per day [45] and involving patients in decision-making
[36, 56] are reflected in previous studies into statin ther-
apy [24, 25, 36], CHD prevention [55], diabetes mellitus
[45] and hypertension [45, 56]. German GPs and inter-
nists had positive attitudes towards combination pills for
hypertension [57] and type 2 diabetes [58]; however, our
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interviewed GPs criticised the inflexible management of
polypills after MI.
Strengths and limitations
To our knowledge, this is the first comprehensive quali-
tative study which examined the prescribing of and non-
adherence to secondary preventive medication following
MI from the perspective of GPs.
Recruitment strategies might have selected GPs who
are better informed and more knowledgeable about this
area than German GPs on average, and participating
GPs might have been more interested in the study’s
topics and consequently more knowledgeable about
them than non-participating GPs.
Our results are not statistically representative due to
the qualitative approach and limited number of inter-
viewees. However, saturation regarding the topics and
themes has been reached. In addition, the sample has a
wide variety regarding the GPs’ age and the number of
GPs in each surgery. The distribution of genders is
nearly equal and the surgeries were located in both
urban and rural regions. Furthermore, Germany had
been divided into two states until 1990, and the surgeries
of our study were located in both former East Germany,
including former East Berlin, and former West Berlin,
which had been aligned to former West Germany.
Moreover, the German healthcare system is mainly
based on federal law. Thus, we assume that the results
are mainly generalisable to GP care in Germany.
The high number of GPs reporting that they adhere to
guidelines points to social desirability effects, which are
balanced by the prompted case narratives.
Conclusions
Our results highlight that guidelines should explicitly ad-
dress multimorbidity and consequential polypharmacy.
They should provide decision aids which take account of
patients’ sex, age, risk factors and comorbidities so that
GPs and patients can make a better-informed prioritisa-
tion of diseases to treat and drugs to use. Decision-aid
software could facilitate these individual prioritisations
and could visualise risks and risk reductions for patients’
understanding [25].
GPs seem to often rely on hospitals’ discharge medica-
tion. Because of the already known insufficient discharge
medication after MI this can lead to insufficient medical
secondary prevention. Thus, the discharge recommenda-
tions should be checked for accordance with the guide-
lines in the hospital, for example automatically by
software, and GPs should be aware of this problem and
should also perform such checks.
GPs partly question the effects of secondary preven-
tion for the oldest of patients. Future research should
address which of the oldest of patients benefit from
medical secondary prevention after MI and which do
not. Results of such studies could help GPs and patients
to assess the benefit from medical secondary prevention
and enable a better-informed decision-making.
In daily practice, GPs should talk with patients who
had an MI about adherence and long-term treatment
goals including their perspective on health. GPs should
assess whether patients are indifferent to their health or
whether there are underlying reasons for non-adherence
which only mimic indifference to health. A trustful part-
nership may be an important resource, and it may be
helpful to assess patients’ motivations through motiv-
ational interviewing to understand this distinction. Fur-
ther studies should address indifference to health
explicitly and its possible association with repression of
health issues, health literacy, health locus of control and
self-efficacy. Improving physicians’ communication skills
and informing and motivating patients in an adequate
manner, for example in simple language, should be an
important goal and should already start in the hospital.
To improve communication skills, training in motiv-
ational interviewing during studies, training and con-
tinuous education might be a possible measure.
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